Harry Ostrer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Harry Ostrer has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
A. Pearlman
New York University School of Medicine, New York, NY
2 shared publicationsA Damle
Division of Biology and Human Genetics, North Shore University Hospital, Manhasset, New York, USA
1 shared publicationA David
Centre Hospitalier Universitaire de Nantes, Nantes, France
1 shared publicationA. C. Pavlick
1 shared publicationA. E. Rose
1 shared publicationAc Galloway
Department of Cardiothoracic Surgery
1 shared publication
Latest Publications
- 12 July 2011
- Published by Wiley in Clinical Genetics
- Vol. 80 (2) , 101-103
Changing the game with whole exome sequencing
- 12 July 2011
- Published by Wiley in Clinical Genetics
- Vol. 80 (2) , 101-103
Changing the game with whole exome sequencing
- 1 November 2010
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 78 (3) , S75
Genome Wide Association Study to Identify Single Nucleotide Polymorphisms (SNPs) Associated with the Development of Erectile Dysfunction in African-American Men following Radiotherapy for Prostate Cancer
- 1 November 2010
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 78 (3) , S75
Genome Wide Association Study to Identify Single Nucleotide Polymorphisms (SNPs) Associated with the Development of Erectile Dysfunction in African-American Men following Radiotherapy for Prostate Cancer
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15_suppl) , 8553
The use of integrative genomics to define molecular signatures of melanoma histologic subtypes.
8553 Background: Studies of c-kit inhibitor imatinib for the treatment of acral melanoma emphasize the importance of delineating and targeting the unique pathways driving tumorigenesis of histologic subtypes. There are no agents specifically tailored to treat the two most common subtypes: superficial spreading (SSM) and nodular melanoma (NM). We integrated gene expression and SNP array data to identify genes and pathways that differentiate NM and SSM. Methods: Gene array (U133A 2.0 Affymetrix) and SNP array (6.0 Affymetrix) were performed on 18 melanoma cell lines (2SSM, 4NM, 12 MET) and 4 melanocyte controls. Gene lists and correlations between DNA copy number and mRNA expression were made using the Partek Genomics Suite. Array data were validated in an expanded group of NM and SSM lines using qRT-PCR, western blot, and an in silico analysis of a public melanoma data set (Jaeger CCR 2007). Immunohistochemistry (IHC) of candidate genes was performed using human tissues from the IMCG. Results: Principal component analysis of gene expression showed high variance among NMs, with all but one falling outside 2 standard deviations of the mean expression for all other melanomas (SSM and MET). mRNA array revealed 114 genes differentially expressed between NM and SSM (p < 0.05, Bonferroni correction). Integrative genomics yielded 14 genes in which expression was significantly correlated with copy number (p < 0.05, Spearman's rank). qRT-PCR verified differential expression between NM and SSM in 7/8 (88%) genes studied, and the same trend between NM and SSM expression of all 7 genes was observed in the external validation set of human tissue. Pathway analysis of the most differentially expressed genes between NM and SSM showed highest representation of metabolic processes (65 genes, 55.1%, p = 0.05). Metabolism-related proteins MTAP and ALDH7A1, and reported tumor suppressor EPB41L3 were assessed by western blot which verified higher expression in NM vs. SSM in all 3 proteins. IHC in human specimens also showed higher levels of ALDH7A1 in NM vs. SSM. Conclusions: Integrative genomics revealed molecular differences between NM and SSM. Data suggest NM and SSM have distinct biology, which may justify different strategies of drug development. No significant financial relationships to disclose.
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15_suppl) , 8553
The use of integrative genomics to define molecular signatures of melanoma histologic subtypes.
8553 Background: Studies of c-kit inhibitor imatinib for the treatment of acral melanoma emphasize the importance of delineating and targeting the unique pathways driving tumorigenesis of histologic subtypes. There are no agents specifically tailored to treat the two most common subtypes: superficial spreading (SSM) and nodular melanoma (NM). We integrated gene expression and SNP array data to identify genes and pathways that differentiate NM and SSM. Methods: Gene array (U133A 2.0 Affymetrix) and SNP array (6.0 Affymetrix) were performed on 18 melanoma cell lines (2SSM, 4NM, 12 MET) and 4 melanocyte controls. Gene lists and correlations between DNA copy number and mRNA expression were made using the Partek Genomics Suite. Array data were validated in an expanded group of NM and SSM lines using qRT-PCR, western blot, and an in silico analysis of a public melanoma data set (Jaeger CCR 2007). Immunohistochemistry (IHC) of candidate genes was performed using human tissues from the IMCG. Results: Principal component analysis of gene expression showed high variance among NMs, with all but one falling outside 2 standard deviations of the mean expression for all other melanomas (SSM and MET). mRNA array revealed 114 genes differentially expressed between NM and SSM (p < 0.05, Bonferroni correction). Integrative genomics yielded 14 genes in which expression was significantly correlated with copy number (p < 0.05, Spearman's rank). qRT-PCR verified differential expression between NM and SSM in 7/8 (88%) genes studied, and the same trend between NM and SSM expression of all 7 genes was observed in the external validation set of human tissue. Pathway analysis of the most differentially expressed genes between NM and SSM showed highest representation of metabolic processes (65 genes, 55.1%, p = 0.05). Metabolism-related proteins MTAP and ALDH7A1, and reported tumor suppressor EPB41L3 were assessed by western blot which verified higher expression in NM vs. SSM in all 3 proteins. IHC in human specimens also showed higher levels of ALDH7A1 in NM vs. SSM. Conclusions: Integrative genomics revealed molecular differences between NM and SSM. Data suggest NM and SSM have distinct biology, which may justify different strategies of drug development. No significant financial relationships to disclose.
- 15 January 2010
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 152A (2) , 422-426
De novo 12;17 translocation upstream of SOX9 resulting in 46,XX testicular disorder of sex development
Individuals with rare cytogenetic variants have contributed to our understanding of the genetics of sex development and its disorders. Here, we report on a child with a de novo 12;17 translocation, 46,XX,t(12;17)(q14.3;q24.3) chromosome complement, resulting in SRY‐negative 46,XX testicular disorder of sex development (46,XX DSD without campomelic dysplasia). The chromosome 12 breakpoint was mapped via array comparative genomic hybridization (aCGH) of a hybrid somatic cell line to 64.2–64.6 Mb (from the p arm telomere). The chromosome 17 breakpoint was mapped to 66.4–67.1 Mb, that is, upstream of SOX9. The location of the chromosome 17 breakpoint was refined by fluorescence in situ hybridization (FISH) at ≥776 kb upstream of SOX9. Thus, the 12;17 translocation removed part of the SOX9 cis‐regulatory region and replaced it with a regulatory element from pseudogene LOC204010 or the next gene, Deynar, of chromosome 12, potentially causing up‐regulation of the testis‐determining SOX9 gene during gonadal development and the phenotype of 46,XX testicular DSD.
- 15 January 2010
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 152A (2) , 422-426
De novo 12;17 translocation upstream of SOX9 resulting in 46,XX testicular disorder of sex development
Individuals with rare cytogenetic variants have contributed to our understanding of the genetics of sex development and its disorders. Here, we report on a child with a de novo 12;17 translocation, 46,XX,t(12;17)(q14.3;q24.3) chromosome complement, resulting in SRY‐negative 46,XX testicular disorder of sex development (46,XX DSD without campomelic dysplasia). The chromosome 12 breakpoint was mapped via array comparative genomic hybridization (aCGH) of a hybrid somatic cell line to 64.2–64.6 Mb (from the p arm telomere). The chromosome 17 breakpoint was mapped to 66.4–67.1 Mb, that is, upstream of SOX9. The location of the chromosome 17 breakpoint was refined by fluorescence in situ hybridization (FISH) at ≥776 kb upstream of SOX9. Thus, the 12;17 translocation removed part of the SOX9 cis‐regulatory region and replaced it with a regulatory element from pseudogene LOC204010 or the next gene, Deynar, of chromosome 12, potentially causing up‐regulation of the testis‐determining SOX9 gene during gonadal development and the phenotype of 46,XX testicular DSD.
- 1 November 2007
- Published by S. Karger AG in Sexual Development
- Vol. 1 (5) , 286-292
A Cellular Study of Human Testis Development
This study catalogs the cellular events underlying the formation of a human testis. These events were identified by immunocytochemistry using antibodies that served as markers for specific cell types, then contrasted with the events occurring in the developing mouse testis. The presence of germ cells in the embryonic gonadal ridge and of coelomic epithelial cells that give rise to Sertoli cells was observed at 7 weeks. This was followed by the appearance of Sertoli cells in testicular tubules and of Leydig cells at 9 weeks and by the appearance of vascular endothelial cells and peritubular myoid cells at 12 weeks. Overall the temporal sequence of events in humans was similar, albeit longer, than what occurs in mice. Notably, Leydig cell differentiation occurs earlier in the sequence of events and germ cell maturation occurs during fetal life. The candidate testis-determining genes, FGF9, GATA4, FOG2, EMX2, and CBX2 were expressed at 7 weeks suggesting a role in early gonadal development, such as that observed in mice. In addition, expression of FGF9 in germ cells following testis determination suggests a role in germ cell maturation.
- 1 November 2007
- Published by S. Karger AG in Sexual Development
- Vol. 1 (5) , 286-292
A Cellular Study of Human Testis Development
This study catalogs the cellular events underlying the formation of a human testis. These events were identified by immunocytochemistry using antibodies that served as markers for specific cell types, then contrasted with the events occurring in the developing mouse testis. The presence of germ cells in the embryonic gonadal ridge and of coelomic epithelial cells that give rise to Sertoli cells was observed at 7 weeks. This was followed by the appearance of Sertoli cells in testicular tubules and of Leydig cells at 9 weeks and by the appearance of vascular endothelial cells and peritubular myoid cells at 12 weeks. Overall the temporal sequence of events in humans was similar, albeit longer, than what occurs in mice. Notably, Leydig cell differentiation occurs earlier in the sequence of events and germ cell maturation occurs during fetal life. The candidate testis-determining genes, FGF9, GATA4, FOG2, EMX2, and CBX2 were expressed at 7 weeks suggesting a role in early gonadal development, such as that observed in mice. In addition, expression of FGF9 in germ cells following testis determination suggests a role in germ cell maturation.
- 2 September 2007
- Published by Wiley in Clinical Genetics
- Vol. 72 (4) , 288-295
The genetics of mitral valve prolapse
Mitral valve prolapse (MVP) is a very common clinical condition that refers to a systolic billowing of one or both mitral valve leaflets into the left atrium. Improvements of echocardiographic techniques and new insights in mitral valve anatomy and physiology have rendered the diagnosis of this condition more accurate and reliable. MVP can be sporadic or familial, demonstrating autosomal dominant and X‐linked inheritance. Three different loci on chromosomes 16, 11 and 13 have been found to be linked to MVP, but no specific gene has been described. Another locus on chromosome X was found to cosegregate with a rare form of MVP called ‘X‐linked myxomatous valvular dystrophy’. MVP is more frequent in patients with connective tissue disorders including Marfan syndrome, Ehlers–Danlos and osteogenesis imperfecta. The purpose of this review is to describe previous studies on the genetics and prevalence of MVP. The report warrants the need for further genetically based studies on this common, albeit not fully understood, clinical entity.
- 2 September 2007
- Published by Wiley in Clinical Genetics
- Vol. 72 (4) , 288-295
The genetics of mitral valve prolapse
Mitral valve prolapse (MVP) is a very common clinical condition that refers to a systolic billowing of one or both mitral valve leaflets into the left atrium. Improvements of echocardiographic techniques and new insights in mitral valve anatomy and physiology have rendered the diagnosis of this condition more accurate and reliable. MVP can be sporadic or familial, demonstrating autosomal dominant and X‐linked inheritance. Three different loci on chromosomes 16, 11 and 13 have been found to be linked to MVP, but no specific gene has been described. Another locus on chromosome X was found to cosegregate with a rare form of MVP called ‘X‐linked myxomatous valvular dystrophy’. MVP is more frequent in patients with connective tissue disorders including Marfan syndrome, Ehlers–Danlos and osteogenesis imperfecta. The purpose of this review is to describe previous studies on the genetics and prevalence of MVP. The report warrants the need for further genetically based studies on this common, albeit not fully understood, clinical entity.
- Open Access
- 2 October 2006
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 116 (10) , 2565
The troubled dream of genetic medicine Ethnicity and innovation in Tay-Sachs, cystic fibrosis, and sickle cell disease
- 2 October 2006
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 116 (10) , 2565
Open AccessThe troubled dream of genetic medicine Ethnicity and innovation in Tay-Sachs, cystic fibrosis, and sickle cell disease
- 7 July 2006
- Published by Wiley in Clinical Genetics
- Vol. 70 (2) , 98-107
Human embryo and early fetus research
Studies of human embryos and fetuses have highlighted developmental differences between humans and model organisms. In addition to describing the normal biology of our own species, a justification in itself, studies of early human development have aided identification of candidate disease genes mapped by positional cloning strategies, understanding pathophysiology, where human disorders are not faithfully reproduced by models in other species, and, more recently, potential therapies based on human embryonic stem and embryonic germ cells. In this article, we review these applications. We also discuss when and how to study human embryo and early fetuses and some of the regulations of this research.
- 7 July 2006
- Published by Wiley in Clinical Genetics
- Vol. 70 (2) , 98-107
Human embryo and early fetus research
Studies of human embryos and fetuses have highlighted developmental differences between humans and model organisms. In addition to describing the normal biology of our own species, a justification in itself, studies of early human development have aided identification of candidate disease genes mapped by positional cloning strategies, understanding pathophysiology, where human disorders are not faithfully reproduced by models in other species, and, more recently, potential therapies based on human embryonic stem and embryonic germ cells. In this article, we review these applications. We also discuss when and how to study human embryo and early fetuses and some of the regulations of this research.
- 1 February 2004
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 10 (5) , 501-511
Alterations of Sex Differentiation in Males: From Candidate Genes to Diagnosis and Treatments
Abstract: Sex, that is, whether one is physically male or female, is the basic dichotomy of life. Sex is important not only for reproductive role, but also for physical attributes, personal identity and disease susceptibility. Sex determination is genetically controlled, with the key event in males being the transmission of a Y chromosome from father to offspring. The sex-determining gene on the Y chromosome, SRY, triggers the expression of a repertoire of other genes that cause the undifferentiated gonad to develop as a testis. Hormones secreted by the developing testis cause the internal and external genitalia to masculinize. Testicular development is disrupted by de novo or inherited genetic alterations leading to gonadal dysgenesis. Decreased hormone production from dysgenetic testes disrupts the normal development of the internal and external genitalia. Incomplete masculinization of the genitalia also occurs from hormonal biosynthetic defects or decreased response to hormones from inherited receptor defects. Treatment is tailored to the individual diagnosis and may include removal of dysgenetic gonads, surgical correction of incompletely masculinized genitalia, replacement of deficient hormones, and, in some instances, gender reassignment.
- 1 February 2004
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 10 (5) , 501-511
Alterations of Sex Differentiation in Males: From Candidate Genes to Diagnosis and Treatments
Abstract: Sex, that is, whether one is physically male or female, is the basic dichotomy of life. Sex is important not only for reproductive role, but also for physical attributes, personal identity and disease susceptibility. Sex determination is genetically controlled, with the key event in males being the transmission of a Y chromosome from father to offspring. The sex-determining gene on the Y chromosome, SRY, triggers the expression of a repertoire of other genes that cause the undifferentiated gonad to develop as a testis. Hormones secreted by the developing testis cause the internal and external genitalia to masculinize. Testicular development is disrupted by de novo or inherited genetic alterations leading to gonadal dysgenesis. Decreased hormone production from dysgenetic testes disrupts the normal development of the internal and external genitalia. Incomplete masculinization of the genitalia also occurs from hormonal biosynthetic defects or decreased response to hormones from inherited receptor defects. Treatment is tailored to the individual diagnosis and may include removal of dysgenetic gonads, surgical correction of incompletely masculinized genitalia, replacement of deficient hormones, and, in some instances, gender reassignment.
- 3 June 2003
- Published by Wiley in Clinical Genetics
- Vol. 63 (6) , 530-535
Mapping a gene for 46,XY gonadal dysgenesis by linkage analysis
46,XY gonadal dysgenesis was transmitted as an autosomal‐dominant trait in a large family with multiple affected members. Expressivity of the trait was highly variable, ranging from pure to partial gonadal dysgenesis associated with normal female genitalia or sexual ambiguity, to mild hypospadias in otherwise normal males. The phenotypic features of this trait appeared to be confined to the genitourinary system. Multipoint parametric analysis using markers D5S664, D5S633, and D5D2102 yielded an LOD score of 4.47, assuming sex‐limited, autosomal‐dominant inheritance with a penetrance of 0.6. Because mutation in testis‐determining genes leads to gonadal dysgenesis in 46,XY individuals, we postulate that the gene mapped by this study normally plays a role in gonadal differentiation.
- 3 June 2003
- Published by Wiley in Clinical Genetics
- Vol. 63 (6) , 530-535
Mapping a gene for 46,XY gonadal dysgenesis by linkage analysis
46,XY gonadal dysgenesis was transmitted as an autosomal‐dominant trait in a large family with multiple affected members. Expressivity of the trait was highly variable, ranging from pure to partial gonadal dysgenesis associated with normal female genitalia or sexual ambiguity, to mild hypospadias in otherwise normal males. The phenotypic features of this trait appeared to be confined to the genitourinary system. Multipoint parametric analysis using markers D5S664, D5S633, and D5D2102 yielded an LOD score of 4.47, assuming sex‐limited, autosomal‐dominant inheritance with a penetrance of 0.6. Because mutation in testis‐determining genes leads to gonadal dysgenesis in 46,XY individuals, we postulate that the gene mapped by this study normally plays a role in gonadal differentiation.